Inventiva to participate at several investor conferences in September 2020

Nachrichtenquelle: globenewswire
09.09.2020, 17:45  |  109   |   |   


Daix
(France), September 9, 2020 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that its management team will participate to five investor conferences in September 2020.


The event details are as follows:

Conference n°1: H.C. Wainwright 22nd Annual Global Investment Virtual Conference
Event type: Corporate presentation, one-on-one investor meetings
Date: Wednesday, September 16, 2020
Time: 11:00 am – 11:20 am (Eastern Time) / 5:00 pm – 5:20 pm (Paris Time)
Format: Virtual presentation
Live link: https://wsw.com/webcast/hcw7/iva/1469344


Conference n°2: 
Roth Analyst Management Talk Series
Event type: Analyst Q/A                      
Date: Monday, September 21, 2020
Time: 12:00 am – 1:00 pm (Eastern Time) / 6:00 pm – 7:00 pm (Paris Time)
Format: Virtual analyst Q/A


Conference n°3: 
KBC Securities Virtual Life Sciences Conference
Event type: Corporate presentation, fireside chat, one-on-one investor meetings
Date: Tuesday, September 22, 2020
Time: 11:00 am – 11:45 am (Eastern Time) / 5:00 pm – 5:45 pm (Paris Time)
(corporate presentation)
Format: Virtual corporate presentation
Live link: https://www.sachsforum.com/20bef-registration.html


Conference n°4: 
20th Annual Biotech in Europe Forum
Event type: Panel discussion
Topic: "Accessing US Capital Markets from Europe Panel"
Date: Tuesday, September 22, 2020
Time: 5:30 am – 6:30 am (Eastern Time) / 11:30 am – 12:30 am (Paris Time)
Format: Virtual panel discussion


Conference n°5: 
Lyon Pôle Bourse Investment Forum
Event type: One-on-one, one-to-few and group investor meetings
Date: Wednesday, September 30, 2020
Time: All day
Format: Hôtel de région, 1 esplanade Francois Mitterand, Lyon, France

About Inventiva 

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need.

Seite 1 von 3
Inventiva Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Diesen Artikel teilen

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Inventiva to participate at several investor conferences in September 2020 Daix (France), September 9, 2020 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), …

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel

Diskussionen zu den Werten

ZeitTitel
12.10.20